Loading publications…
The last 5 uploaded publications
DOACs in patients with brain cancers: promising but still a long way to go
Michela Giustozzi, Cecilia Becattini, Fausto Roila, Giancarlo Agnelli, Mario Mandalà (2022). DOACs in patients with brain cancers: promising but still a long way to go. , 7(2), DOI: https://doi.org/10.1182/bloodadvances.2022009192.
Letter76 days agoICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis
Michela Giustozzi, Giulia Proietti, Cecilia Becattini, Fausto Roila, Giancarlo Agnelli, Mario Mandalà (2022). ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis. , 6(16), DOI: https://doi.org/10.1182/bloodadvances.2022008086.
Article76 days agoTreatment of venous thromboembolism in cancer patients: The dark side of the moon
Cecilia Becattini, Marcello Di Nisio, Laura Franco, Agnes Y.Y. Lee, Giancarlo Agnelli, Mario Mandalà (2021). Treatment of venous thromboembolism in cancer patients: The dark side of the moon. , 96, DOI: https://doi.org/10.1016/j.ctrv.2021.102190.
Article76 days ago1684P Cardiovascular events with immune checkpoint inhibitors in melanoma or NSCLC: A systematic review and meta-analysis
Mario Mandalà, Cecilia Becattini, F. Roila, Giancarlo Agnelli, Michela Giustozzi (2021). 1684P Cardiovascular events with immune checkpoint inhibitors in melanoma or NSCLC: A systematic review and meta-analysis. , 32, DOI: https://doi.org/10.1016/j.annonc.2021.08.1656.
Article76 days agoVascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis
Michela Giustozzi, Cecilia Becattini, Fausto Roila, Giancarlo Agnelli, Mario Mandalà (2021). Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis. , 100, DOI: https://doi.org/10.1016/j.ctrv.2021.102280.
Article76 days ago